Prospects rise for world's first national screening
program.
STOCKHOLM and LUND, SWEDEN, Aug 3,
2018 /PRNewswire/ --
Immunovia AB today announced that the Karolinska
Institutet is to participate in PanFAM-1, the largest ever
prospective study looking at early diagnosis in high-risk
individuals with Familial Pancreatic Cancer (FPC). Designed to
validate Immunovia ́s innovative blood test, IMMray™ PanCan-d, the
study will analyze more than thousand individuals over three
years across sites in Sweden, the
US and Europe already offering FPC
screening programs. The aim is to improve the outcome for the
cancer patients and to prove the overall healthcare benefits of
testing persons with heredity for pancreatic cancer. In
Sweden, the early participation of
nearly all key centers raises the possibility of creating a
national screening program. Parallel to this Immunovia is also
running a study for another newly identified high risk
group, new onset diabetics over 50 years of age.
"When it has been possible to intervene early with surgery we
have had been able to significantly raise survival rates in our
clinic, as has been the case with our colleagues in the other sites
involved in PanFAM-1," says PI Dr Urban Arnelo of the Pancreatic
Surgery Unit, Division of Surgery, Department of Clinical Science,
Intervention and Technology (CLINTEC) Karolinska Institutet. "However, we still lack
accurate, non-invasive early diagnostic tools and are now
interested to participate in the study to see if IMMray™ PanCan-d
could provide the answer."
"We are delighted that Karolinska
Institutet participates in the PanFAM-1 study for two
reasons. Firstly this marks a major step forward as we aim to
establish a national program for early detection of pancreatic
cancer among major risk groups here in Sweden and secondly because of their worldwide
reputation as a center of excellence in oncology," commented
Mats Grahn, CEO, Immunovia.
The other PanFAM-1 partners to date are: Mount Sinai, New York; Knight Cancer
Institute at Oregon Health and Sciences University, Portland, OR; The University of Pittsburgh Medical Center
Pittsburgh, PA; The
Massachusetts General Hospital, Boston,
MA; NYU School of Medicine, New York; The University of Liverpool, UK; Ramon y Cajal
Institute for Health Research Madrid,
Spain; University Hospital of Santiago de Compostela, Spain, Clínica Universidad de
Navarra, Spain; and Linköping
University Hospital and Sahlgrenska University Hospital,
Gothenburg - both in Sweden. Advanced discussions over potential
participation continue with several other European and US centers
running high risk surveillance programs.
About Immunovia
Immunovia AB was founded in 2007 by investigators from the
Department of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases
diagnosis, prognosis and therapy monitoring. The first test from
this program, IMMray™ SLE-d, is a biomarker signature derived for
differential diagnosis of lupus, now undergoing evaluation and
validation. (Source: www.immunovia.com)
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
About Pancreatic Cancer
Pancreatic Cancer is one of the most deadly and difficult to
detect cancers, as the signs and symptoms are diffuse and similar
to other diseases. There are more than 40,000 deaths and over
50,000 new cases diagnosed each year in the U.S. alone, and the
five-year survival rate for pancreatic cancer is currently 5-8 %.
It is predicted to become the second leading cause of cancer death
by 2020. However, because resection is more successful in stage
I/II, early diagnosis can significantly improve pancreatic cancer
patients' 5-year survival rates from 5-8 % to up to 49%.
CONTACT:
For more information, please contact:
Mats Grahn
Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230
Email: mats.grahn@immunovia.com
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/immunovia-ab/r/karolinska-institutet-participates-in-immunovia-s-panfam-1-prospective--clinical-study-for-early-det,c2586070
The following files are available for download:
http://mb.cision.com/Main/13121/2586070/886687.pdf
|
Press release
Immunovia Karolinska PanFAM-1
|
View original
content:http://www.prnewswire.com/news-releases/karolinska-institutet-participates-in-immunovias-panfam-1-prospective-clinical-study-for-early-detection-of-pancreatic-cancer-using-blood-based-test-300691785.html
SOURCE Immunovia AB